Active Biotech in Brief

Active Biotech develops pharmaceutical products within medical areas where the immune defense is of significant importance, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.

  • Swedish Biotechnology Company based in Lund
  • Core competence in cancer and inflammatory diseases
  • Company founded in 1998, spun out from Pharmacia
  • Listed company NASDAQ OMX Nordic: ACTI
  • Competent team with extensive experience in drug development from early to late stage clinical development
  • Partnership with NeoTX Therapeutics Ltd., for the development and commercialization of naptumomab estafenatox for cancer immunotherapy

On February 5, 2020, new direction for the company was announced and the project portfolio is now composed of:

  • Naptumomab estafenatox, licensed to NeoTX Therapeutics Ltd., is in development for treatment of solid tumors. The project is currently in clinical phase 1b/2
  • Tasquinimod for treatment of multiple myeloma. The project is in an academic partnership with The Perelman School of Medicine, University of Pennsylvania, and preparation for a phase 1b/2a study is ongoing
  • Laquinimod for treatment of the eye disorders wet AMD and uveitis. Pre-clinical activities are ongoing to increase the understanding of the therapeutic potential of laquinimod in these diseases
  • Laquinimod for treatment of Crohn’s disease. A prior clinical Phase 2a study provides compelling data for the use of laquinimod in this indication. The possible partnership modalities, including academic partnerships, to advance use of laquinimod for this indication will be explored
Where the immune defense is of significant importance